Faculty and fellows of the Division of Pediatric Hematology-Oncology are engaged in a wide range of clinical, translational and basic investigation related to pediatric cancer, disorders of the blood including clotting or bleeding problems, and the quality of life of children and their families undergoing severe medical conditions.
Areas of Special Interest
|Lars Martin Wagner, MD, Chief||Solid tumors, combination therapies for sarcoma|
|Nancy Catherine Andrews, MD, PhD||Molecular processes governing iron disease, such as anemia and hemochromatosis|
|Raymond Carlton Barfield, MD, PhD||Study of the intersection of medicine, theology, philosophy, and literature in an attempt to improve the quality of life of children and their families experiencing severe medical illness.|
|Michael D. Deel, MD||Gene regulation and molecular pathways responsible for alveolar rhabdomyosarcoma|
|Susan Kreissman, MD||
Improving the treatment of neuroblastoma through the study of new treatment plans, coordinating multidisciplinary care for retinoblastoma patients, leading national inquiry in COG neuroblastoma treatment studies.
|Daniel Bryce Landi, MD||Development and implementation of novel immune-based therapies|
|Corinne Linardic, MD, PhD||The study of childhood rhabdomyosarcoma, using primary cell-based and xenograft models to understand the implicated signaling pathways and to identify potential therapeutic targets.|
|Bernard Mathey-Prevot, PhD||Study of how signaling pathway architecture and integration result in specific cell fates and how these properties have been hijacked in cancer cells|
|Kristy Pahl, MD||Pediatric cancer, bleeding disorders, vascular malformations|
|Jennifer Rothman, MD||
Benign hematology, including congenital hemolytic anemia, sickle cell disease, immune thrombocytopenia, aplastic anemia and bone marrow failure syndromes.
|Kristin M. Schroeder, MD||
Improving outcomes for pediatric cancer patients in low resource countries, including creating diagnostic algorithms to predict patients with lymphoma in areas where biopsy may not be readily available, as well as evaluating the factors contributing to high treatment abandonment rates among pediatric cancer patients.
|Nirmish Ramesh Shah, MD||
Novel therapeutic options for patients with sickle cell disease; transition from pediatric to adult care for sickle cell disease; and use of mobile technology to advance patient care for sickle cell disease; use of wearables to provide objective data to combine with subjective symptoms in patients with sickle cell disease, cancer and bone marrow transplant who have pain.
|John J. Strouse, MD, PhD||My research focuses on the epidemiology, risk factors, and prevention of the pulmonary and central nervous system complications of sickle cell disease and includes retrospective and prospective cohort studies and clinical trials.|
|Jessica Muller Sun, MD||
Developing umbilical cord blood-derived therapies for the treatment of childhood genetic and acquired neurologic disorders.
|David Sinclaire Van Mater, MD||
Factors that impact sarcoma formation; clinical studies that impact oncologic sequelae of neurofibromatosis.
For further information about clinical trials currently being conducted in the Division of Hematology-Oncology, please visit dukechildrens.org.